3SOF

There was a Huge volume GAP up on Friday.
Should be 15 to 20 % higher...

I will buy after 62 % Fib retracement of the GAP day candle around 21.4$.


news:
http://biz.yahoo.com/cbsmb/050701/ffe1e5d1d7604c73a2b3732ae55d6510.html?.v=1

I agree with you completely, 21.40 is a good entry point heading to 25.00
                                    NyGuy

http://finance.yahoo.com/q/bc?s=NTMD&t=1d&l=on&z=m&q=l&c=

Will be watching closely.  Took some profit off the table.
Buying again on a dip. 

Strong chart 

Watch the close.  Alot of Green on Level 2.

http://finance.yahoo.com/q/bc?s=NTMD&t=1d

Bought more.  Strong chart for next week.

NTMB>  NitroMed, Inc., a pharmaceutical company, engages in the research, development, and commercialization of pharmaceuticals based on the therapeutic benefits of the molecule nitric oxide

Second Quarter 2005 Financial Results Conference Call August 3 at 5:00 pm ET

OK guys, this company is in the process of launching its first drug BiDil for treating Afican Americans heart cancer. 

Finance:  It will have an initail raise this week. It will then dip due toinitail distribution of samples, high co-payments in these upcoming months.   I however will go long, buy every week(dollar cost average this sucker)  and see forcasts of 90.00 (310%) high and a low target price of 60.00 (175%)

THis is not a pump, received information on Sharebuilder, ameritrade, yahoo and valueline.



Add to Watch List  |  What If I Had Invested?

sorry for the repost fill the gap.  just saw yours.  You got in at 20.  very nice.  it went up 3.00 this week alone.  Like i said before, i think it will have jumps this week if you can time it right.  I just believe its going to be a double bagger in the future and with out the risk.

I think it is ready now for some short term profit.

Appears to have bottomed.
Stock is improving with higher highs and higher lows... One of the best early indicators for the stock moving higher. Besides, Crammer likes it...LOL 

NitroMed develops nitric oxide-enhancing medicines for various therapeutic areas, such as hypertension, edema, acute renal failure, pain, inflammation, cancer, asthma, male erectile dysfunction, chronic obstructive airway disease, allergy, dermatology, peptic ulcer, kidney failure, cystic fibrosis, and other central nervous system diseases.

52wk Range: 2.04 - 13.33
Volume: 1,776,195
Avg Vol (3m): 324,967

Technicals
Last Price Quote is:
16.35%above 13-day MA
18.72%above 50-day MA
RS Rating: 84 

Fundamentals
Key Data:
Market Cap (M): $108.17 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/08/2007
Last Analyst Rating: Sell

"NTMD" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.      
All history on a stock pick in 1 thread is awesome.       

Thank You....and good luck with all your trades....make some $$$     

Sure is looking nice.......


52wk Range: 2.04 - 12.25
Volume: 1,996,151
Avg Vol (3m): 406,772

Technicals
MACD - Bullish
Percentage Gainer

Last Price Quote is:
15.26%above 13-day MA
35.23%above 50-day MA
RS Rating: 97 

Fundamentals
Key Data:
Market Cap (M): $108.17 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/08/2007
Last Analyst Rating: Sell

 Feb 12 (Reuters) - Nitromed Inc. (NTMD,Trade) said it signed a license agreement with Elan Pharma International Ltd. to develop an extended release formulation of BiDil, its drug targeted at African-American patients with heart diseases.

In exchange for certain know-how, patents and technology, Nitromed has agreed to pay royalties to Elan, Nitromed said in a regulatory filing. (Reporting by Jennifer Robin Raj in Bangalore)




(Adds dateline, details)

BANGALORE, Feb 12 (Reuters) - Nitromed Inc. (NTMD,Trade) said it would use certain know-how and technology from Elan Corp. Plc.'s ((ELN.I))(ELN,Trade) Elan Pharma International Ltd. unit to develop a once-a-day version of its BiDil heart drug.

Shares of Lexington, Massachusetts-based NitroMed were up almost 11 percent at $3.86 in afternoon trade on the Nasdaq.

Under the licensing deal, Nitromed would pay royalties to Elan, Nitromed said in a regulatory filing on Monday.

The company had in last October fired its sales team, saying that it wanted to focus resources on development of an extended-release version of BiDil, which is targeted at African-American patients.

BiDil currently needs to be taken thrice daily, Nitromed spokeswoman Jane Kramer said.

NitroMed had launched BiDil, its only product, in mid-2005 and had forecast sales of $20 million from it in 2006.

However, the company sold only $8.6 million worth of BiDil in the first nine months of last year. (Reporting by Jennifer Robin Raj in Bangalore)